Bristol's Abilify gets expanded FDA approval

02/28/2008 | Bloomberg

Abilify, an antipsychotic drug from Bristol-Myers Squibb Co., has received additional FDA clearance for the treatment of bipolar disorder in children 10 years and older. The company currently markets the drug for schizophrenia patients aged 13 and up and adults with bipolar disorder and major depression.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ